by The immunology market size is poised to grow by USD 263.22 billion by 2033 from USD 98.22 billion in 2023, exhibiting a CAGR of 10.36% during the forecast period 2024-2033.
Key Points
- North America held the largest share of 53% in 2023.
- Asia Pacific is observed to witness the fastest rate of expansion during the forecast period.
- By drug class, the monoclonal antibodies segment held the largest share of the market.
- By disease indication, the rheumatoid arthritis segment held the largest share of the market.
- By distribution channel, the hospital pharmacies segment held the largest share of the market.
Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Immunology market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.
To begin with, the Immunology Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.
Get a Sample Report: https://www.precedenceresearch.com/sample/3867
Immunology Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 10.36% |
| Global Market Size in 2023 | USD 98.22 Billion |
| Global Market Size by 2033 | USD 263.22 Billion |
| U.S. Market Size in 2023 | USD 39.04 Billion |
| U.S. Market Size by 2033 | USD 104.63 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Drug Class, By Disease Indication, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Fuel Card Market Size to Rake USD 2,610.37 Billion by 2033
The empirical study on the global Immunology market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Immunology Market. Our market report for the Immunology market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
Immunology Market Companies
- AbbVie Inc.
- Janssen Global Services, LLC (Johnson & Johnson)
- Novartis AG.
- ALLERGAN.
- Amgen Inc.
- Other Prominent Players.
- Merck Sharp & Dohme Corp.
- Bristol-Myers Squibb Company.
Data Sources and Methodology
To gather comprehensive insights on the Global Immunology Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Immunology Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Immunology market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2024 to 2033.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Market Segmentation:
By Drug Class
- Monoclonal Antibodies
- Fusion Proteins
- Immunosuppressants
- Others
By Disease Indication
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Inflammatory Bowel Disease
- Prophylaxis Of Organ Rejection
By Distribution Channel
- Hospital Pharmacie
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Immunology market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Immunology market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Immunology market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Immunology market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Immunology Market
5.1. COVID-19 Landscape: Immunology Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Immunology Market, By Drug Class
8.1. Immunology Market, by Drug Class, 2024-2033
8.1.1 Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Fusion Proteins
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Immunosuppressants
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Immunology Market, By Disease Indication
9.1. Immunology Market, by Disease Indication, 2024-2033
9.1.1. Rheumatoid Arthritis
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Psoriatic Arthritis
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Plaque Psoriasis
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Ankylosing Spondylitis
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Inflammatory Bowel Disease
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Prophylaxis Of Organ Rejection
9.1.6.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Immunology Market, By Distribution Channel
10.1. Immunology Market, by Distribution Channel, 2024-2033
10.1.1. Hospital Pharmacie
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Immunology Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
Chapter 12. Company Profiles
12.1. AbbVie Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Janssen Global Services, LLC (Johnson & Johnson)
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. ALLERGAN.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Amgen Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Other Prominent Players.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck Sharp & Dohme Corp.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bristol-Myers Squibb Company
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Unlocking Market Insights through Data Excellence
The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
Precedence Statistics – Empowering Your Data Insights
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
